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September 21, 2010:1034–41 Lipid Combinations, CIMT, and CACssociation of Combinations of Lipid Parameters With
arotid Intima-Media Thickness and Coronary Artery Calcium
n the MESA (Multi-Ethnic Study of Atherosclerosis)
Objectives The purpose of this study was to determine the association of combinations of lipid parameters with subclinical
atherosclerosis.
Background Carotid intima-media thickness (CIMT) and coronary artery calcium (CAC) are significantly associated with incident
cardiovascular disease (CVD). The association between common dyslipidemias (combined hyperlipidemia, [simple]
hypercholesterolemia, dyslipidemia of metabolic syndrome, isolated low high-density lipoprotein cholesterol, and iso-
lated hypertriglyceridemia) compared with normolipemia, and CIMT and CAC has not been previously examined.
Methods The MESA (Multi-Ethnic Study of Atherosclerosis) participants were White, Chinese, African-American, or His-
panic adults without clinical CVD. Subjects with diabetes mellitus or who were receiving lipid-lowering therapy
were excluded. Every participant was classified into only 1 of 6 groups defined by specific low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol, or triglyceride cut points. Multivariate linear and relative risk
regressions evaluated the cross-sectional associations with CIMT and CAC after adjusting for CVD risk factors.
Interactions with race, sex, and high-sensitivity C-reactive protein were evaluated for CIMT and CAC outcomes.
Results Among 4,792 participants, only those with combined hyperlipidemia and hypercholesterolemia demonstrated both
increased common CIMT (combined hyperlipidemia 0.048 mm thicker, 95% confidence interval [CI]: 0.016 to 0.080
mm; hypercholesterolemia 0.048 mm thicker, 95% CI: 0.029 to 0.067 mm) and internal CIMT (combined hyperlipid-
emia 0.120 mm thicker, 95% CI: 0.032 to 0.208 mm; and hypercholesterolemia 0.161 mm thicker, 95% CI: 0.098
to 0.223 mm) as well as increased risk for prevalent CAC (combined hyperlipidemia relative risk: 1.22, 95% CI: 1.08
to 1.38; hypercholesterolemia relative risk: 1.22, 95% CI: 1.11 to 1.34) compared with normolipemia. The interactions
between lipid parameters and race, sex, or high-sensitivity C-reactive protein were not significant for any outcomes.
Conclusions Combined hyperlipidemia and simple hypercholesterolemia were associated with increased CIMT and prevalent
CAC in a relatively healthy multiethnic population. (J Am Coll Cardiol 2010;56:1034–41) © 2010 by the
American College of Cardiology Foundationc
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cyslipidemia is one of the most important risk factors for
oronary heart disease (CHD) worldwide (1). Dyslipi-
emias vary in phenotypic expression because of the inter-
ction of polygenic and environmental influences. Current
uidelines are based on specific low-density lipoprotein
holesterol (LDL-C) cut points as primary targets (2).
See page 1042
owever, persons with dyslipidemia often also have abnormal-
ties in high-density lipoprotein cholesterol (HDL-C) and/or
riglycerides, which also have strong and independent associ-
tions with incident CHD (2–5). We have defined the 5 major
yslipidemias, combined hyperlipidemia, hypercholesterol-
mia, dyslipidemia of metabolic syndrome (MetS), low
DL-C, and hypertriglyceridemia (Table 1), using criteria
ased on current National Cholesterol Education Program
NCEP)/Adult Treatment Panel (ATP)-III guidelines that
efine LDL-C, HDL-C, and triglyceride thresholds as abnor-
al (2). The biological rationale for classifying these lipid
arameters is that these common combinations of lipid param-
ters capture the complexity of having more than 1 abnormal
ipid parameter as often seen in patients at risk for cardiovas-
ular disease (CVD). NWe evaluated the relationship of these 5 dyslipidemias
ompared with normolipemia (NL) with carotid intima-media
hickness (CIMT) and coronary artery calcium (CAC) in a
opulation free of clinically recognized CVD and diabetes
ellitus. We sought to determine whether there is an inde-
endent association beyond other CVD risk factors of the
ombination of lipid parameters with subclinical atherosclerosis.
Beyond dyslipidemia, high-sensitivity C-reactive protein
hsCRP) has also been evaluated as a risk marker and is
ndependently associated with incident CVD (6). Consid-
ring the recent JUPITER (Justification for the Use of
tatins in Primary Prevention: An Intervention Trial Eval-
ating Rosuvastatin) study (7), which included subjects with
DL-C 130 mg/dl and hsCRP 2 mg/l, we also evalu-
ted whether hsCRP at a cut point of 2 mg/l modified the
ssociation of combination of lipid parameters with CIMT
nd CAC. Finally, we evaluated whether race/ethnicity or
ex modified the association of combination of lipid param-
ters with CIMT and CAC.
ethods
he MESA (Multi-Ethnic Study of Atherosclerosis) study
s a prospective evaluation of subclinical CVD in 6,814
ommunity-dwelling men and women sponsored by the
ational Heart, Lung, and Blood Institute. Participants
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Lipid Combinations, CIMT, and CAC September 21, 2010:1034–41were age 45 to 84 years and free
of known CVD at the baseline
examination (2000 to 2002).
They belong to 4 racial/ethnic
groups: white, Chinese, His-
panic, and African American. Par-
ticipants participated through 6
field centers located in Forsyth
County, North Carolina; St.
Paul, Minnesota; Chicago, Illi-
nois; New York, New York; Bal-
timore, Maryland; and Los An-
geles County, California. At
each study center, human sub-
jects institutional review boards
approved the study protocol.
Every participant provided in-
formed consent. Further details
regarding the design and objec-
tives of the MESA study can be
found elsewhere (8).
Study population. Subjects with
diabetes mellitus (confirmed base-
line fasting glucose126 mg/dl or
receiving diabetes medication) or
ith missing data for diabetes were excluded from this analysis
n  883) because diabetes is considered a CHD equivalent
nd because of the strong independent relationship of diabetes
ith low HDL-C and elevated triglycerides, CAC, and
ncreased CIMT. Subjects receiving lipid-lowering therapy
ere excluded because lipid lowering has a substantial impact
n all lipid parameters as well as on CIMT (n 808). Finally,
ubjects with missing values for lipid parameters, CIMT
easurements, or missing covariates were excluded (total n 
31). The final sample size for our analysis was 4,792
articipants.
aseline measurements. Age and race/ethnicity were self-
eported. Cardiovascular risk factors were measured or
ollected, and included height, weight, and waist circum-
erence, medical history including presence of diabetes
defined using the 2003 American Diabetes Association
riteria of a fasting glucose 126 mg/dl or taking medica-
ions for diabetes), hypertension (defined as systolic blood
efinition of Lipid Parameter Combinationsn MESA 2000 to 2002Table 1 Definition of Lipid Parame er Combinationsin MESA 2000 to 2002
HDL-C
(mg/dl)
LDL-C
(mg/dl)
Triglycerides
(mg/dl)
Normolipemia 40 men, 50 women 160 150
Combined hyperlipidemia No cutoff 160 150
Hypercholesterolemia No cutoff 160 150
MetS dyslipidemia 40 men, 50 women 160 150
Low HDL-C 40 men, 50 women 160 150
Hypertriglyceridemia 40 men, 50 women 160 150
Abbreviations
and Acronyms
CAC  coronary artery
calcium
CHD  coronary heart
disease
CI  confidence interval
CIMT  carotid intima-
media thickness
CVD  cardiovascular
disease
HDL-C  high-density
lipoprotein cholesterol
hsCRP  high-sensitivity
C-reactive protein
LDL-C  low-density
lipoprotein cholesterol
MetS  dyslipidemia of
metabolic syndrome
NCEP  National
Cholesterol Education
Program
NL  normolipemia
RR  relative riskc
DL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; MESA
ulti-Ethnic Study of Atherosclerosis; MetS  metabolic syndrome.ressure 140 mm Hg at baseline visit, or diastolic blood
ressure 90 mm Hg, or by a history of physician-
iagnosed hypertension and taking a medication for hyper-
ension), and assessment of personal habits such as alcohol
nd tobacco use. Highest level of education completed as a
easure of socioeconomic status was also captured.
Fasting triglycerides were measured in plasma using a
lycerol blanked enzymatic method (Trig/GB, Roche Di-
gnostics, Indianapolis, Indiana). Cholesterol was measured
n plasma on the Hitachi 911 using a cholesterol esterase,
holesterol oxidase reaction (Chol R1, Roche Diagnostics).
he same reaction was also used to measure HDL-C after
recipitation of non–HDL-C with magnesium/dextran.
he LDL-C was calculated on specimens having a triglyc-
ride of 400 mg/dl using the Friedewald formula (9). The
DL-C as determined by nuclear magnetic resonance
pectroscopy was used instead of calculated LDL-C for
ubjects with triglycerides 400 mg/dl (10).
Serum glucose was measured using the glucose oxidase
ethod on the Vitros analyzer (Johnson & Johnson, Roches-
er, New York). Insulin was measured in serum by an immu-
oenzymatic sandwich assay using Access Ultrasensitive insu-
in reagent on the Access immunoassay system (Beckman
nstruments, Fullerton, California). The C-reactive protein
as measured using the BNII nephelometer (High Sensitivity
RP, Dade Behring, Deerfield, Illinois). Creatinine was mea-
ured by rate reflectance spectrophotometry using thin film
daptation of the creatinine amidinohydrolase method on the
itros analyzer (Johnson & Johnson).
efinition of lipid parameters. Table 1 identifies the
arious HDL-C, LDL-C, and triglyceride cutoffs used to
efine each dyslipidemia. Categories are designed to be
utually exclusive. For example, if someone has low HDL
nd elevated triglycerides, they would be classified in the
etS dyslipidemia and not in the low HDL group. Partic-
pants are classified based on the most severe dyslipidemia.
hus, everyone is categorized into only 1 lipid group.
IMT. The intima-media layer of the carotid arterial wall
as measured using high-resolution B-mode ultrasonogra-
hy of the near and far walls of the left and right common
nd internal carotid arteries (11). The mean maximum value
f the common and internal CIMT was evaluated sepa-
ately. The intraclass correlation coefficients for intrareader
nd inter-reader reproducibility were 0.98 and 0.86, respec-
ively, for common carotid measurements, and 0.99 and
.94 for internal carotid measurements. A standardized
rotocol with quality control procedures was used and
nterpretation was done at a centralized reading station,
ew England Medical Center, Boston, Massachusetts
11,12). Analyses for the association of lipid parameters
ith common and internal CIMT were performed inde-
endently (13).
AC. The Agatston scoring method was used to quantify
aseline CAC, which was an average of 2 measurements
14). The CAC was measured either by electron-beam
omputed tomography or by multidetector row helical
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September 21, 2010:1034–41 Lipid Combinations, CIMT, and CAComputed tomography, depending on the field center.
nterobserver agreement (  0.93) and intraobserver
greement (  0.90) were very high (15). Careful quality
ontrol and standardized protocols were used at each clinical
ite, and biweekly phantom scans were performed to assure
quivalence among sites (16). Detection of CAC was
efined by a minimum of 130 Hounsfield units. Details
egarding the protocol, acquisition, and interpretation of
AC scans in the MESA study have been reported previ-
usly (16).
tatistical analyses. We conducted a cross-sectional analysis
o evaluate the association of combination of lipid parameters
ith CIMT and CAC. Skewed covariates such as insulin and
RP were log transformed. Important covariates that were
dentified a priori and included in the model were age,
ace/ethnicity, sex, clinical site, education, history of hyperten-
ion, current smoking status, alcohol use, estrogen use among
omen, waist circumference, fasting glucose, fasting insulin,
RP, and creatinine.
Multivariate linear regression was used in analyses of CIMT
s a continuous outcome. We used multivariate linear regres-
ion methods with robust standard errors, which provide valid
nference even when individual outcomes do not satisfy the
tandard assumptions of constant variance and normality (17).
ultivariate relative risk regression was used in analyses when
AC was a dichotomous outcome, defined as subjects with
AC versus those without CAC. A p value 0.05 was
onsidered significant. Interaction of race/ethnic group and
ipid parameters on common and internal CIMT and preva-
ent CAC was assessed in separate models. Interaction of sex
nd lipid parameters on common and internal CIMT and
revalent CAC was assessed in separate models. The interac-
ion of hsCRP dichotomized as 2 and 2 mg/l and lipid
arameters on common and internal CIMT and prevalent
AC was assessed in separate models. A p value 0.05 was
onsidered significant for interactions. All analyses were per-
ormed using STATA version 10.0 for Windows (StataCorp.,
ollege Station, Texas).
esults
very subject was classified into only 1 lipid group. Table 2
escribes the mean, minimum, and maximum values for
DL-C, HDL-C, and triglycerides to demonstrate accurate
Mean, Minimum, and Maximum Values for HDL-Triglycerides for Each Lipid Parameter C mbinatTable 2 Mean, Minimu , and Maximum V lTriglycerides for Each Lipid Parame
HDL-C (mg
Normolipemia (n  2,310) 60.9 (41.0, 1
Combined hyperlipidemia (n  171) 44.4 (24.0, 6
Hypercholesterolemia (n  331) 52.2 (30.0, 9
MetS dyslipidemia (n  736) 37.6 (15.0, 5
Low HDL-C (n  876) 40.3 (21.0, 5
Hypertriglyceridemia (n  368) 54.0 (40.1, 9Values are mean (minimum, maximum).
Abbreviations as in Table 1.lassification of combination of lipid parameters. Baseline
haracteristics of the total study population and by lipid
arameters are shown in Table 3. Of 4,792 participants,
ore than one-half of the participants had dyslipidemia.
orty-eight percent were classified as NL, 4% as combined
yperlipidemia, 7% as hypercholesterolemia, 15% as MetS,
8% as low HDL, and 8% as hypertriglyceridemia. Fifty-
hree percent of all participants were women, and the mean
ge was 61 years. The racial/ethnic breakdown of the study
opulation was 40% White, 12% Chinese, 26% African
merican, and 22% Hispanic. Participants who were NL
ere more likely to have completed high school. Partici-
ants who were NL or had hypertriglyceridemia were more
ikely to actively drink alcohol. Participants with MetS were
ore likely to smoke. Participants with MetS or hypertri-
lyceridemia were more likely to have hypertension.
omen with hypertriglyceridemia were more likely to use
strogen. The NL participants had the lowest mean waist
ircumference, glucose, insulin, and hsCRP. Participants
ith combined hyperlipidemia and MetS had the highest
ramingham/NCEP 10-year CHD risk scores. However,
ean risk scores were rather low in all groups. (Compari-
ons of each dyslipidemia to another [pair-wise compari-
ons] are presented in Online Table 4.)
IMT findings. After adjustment for demographic and
VD risk factors, only combined hyperlipidemia and hy-
ercholesterolemia had significantly higher mean maximum
nternal CIMT than NL (Fig. 1, blue lines). After adjust-
ent for demographic and CVD risk factors, only com-
ined hyperlipidemia, hypercholesterolemia, and low HDL
ad significantly higher mean maximum common CIMT
ompared with NL (Fig. 1, red lines).
AC findings. After adjustment for demographic and
VD risk factors, only subjects with combined hyperlipid-
mia, hypercholesterolemia, and MetS had increased rela-
ive risk for prevalent CAC (Fig. 2).
nteraction by race/ethnicity. The p value for interaction
etween race and lipid parameters was not significant for
ommon or internal CIMT (p  0.3 and p  0.1,
espectively) or prevalent CAC (p  0.6). However, an
ssociation of lipid parameters with CIMT and CAC
tratifying by race/ethnicity (Online Table 5) shows
ypothesis-generating trends.
L-C, andn MESA 2000 to 2002or HDL-C, LDL-C, and
ombination in MESA 2000 to 2002
LDL-C (mg/dl) Triglycerides (mg/dl)
113 (26.0, 159) 85.8 (21.0, 149)
179 (160, 274) 214 (151, 466)
177 (160, 284) 104 (39.0, 149)
114 (21.0, 159) 224 (150, 873)
114 (28.0, 159) 103 (24.0, 149)
122 (20.0, 159) 199 (150, 457)C, LDion iues f
ter C
/dl)
42)
7.0)
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Lipid Combinations, CIMT, and CAC September 21, 2010:1034–41nteraction by sex. The p value for interaction between sex
nd lipid parameters was not significant for common or
nternal CIMT (p  0.5 and p  0.07, respectively) or
revalent CAC (p  0.5). However, an association of lipid
arameters with CIMT and CAC stratifying by sex (Online
able 6) shows hypothesis-generating trends.
nteraction by hsCRP. The p value for interaction of
sCRP dichotomized at the cut point of 2 mg/l with lipid
arameters was not significant for internal or common CIMT
p  0.6 and p  0.3, respectively) or prevalent CAC (p 
.5). However, an association of lipid parameters with CIMT
nd CAC stratifying by hsCRP (Online Table 7) shows
ypothesis-generating trends.
iscussion
his is the first analysis examining the relationship between
yslipidemia as classified by combinations of lipid parame-
ers with subclinical atherosclerosis as measured by CIMT
nd CAC within the same cohort. We demonstrate in a
ultiethnic U.S. population without diabetes or known
linical CVD that subjects with combined hyperlipidemia
nd hypercholesterolemia have increased internal and com-
ubject Characteristics (MESA 2000 to 2002) as Classified by CoTable 3 Subject Characteristics (MESA 2000 to 2002) as Clas
All NL
Com
Hyperl
n (%) 4,792 2,310 (48) 171 (4
Age, yrs† 61 (10) 62 (11) 61 (1
Women, %* 53 55
Race, %*
White 40 42
Asian (Chinese) 12 12
African American 26 30
Hispanic 22 16
Framingham-NCEP CHD risk, %* 7.8 (7.1) 6.3 (5.9) 11.3 (8
Completed high school, %* 84 88
Alcohol use, %*
Never drank 20 17
Formerly drank 22 21
Currently drinks 58 62
Current smokers, %† 14 12
Hypertension, %† 39 37
Estrogen use, women, %* 28 32
Waist circumference, cm* 96 (14) 93 (14) 100 (1
Glucose, mg/dl* 89 (9.5) 87 (9.2) 92 (9
Insulin, mU/l* 5.0 (3.4–7.8) 4.0 (2.8–6.0) 6.2 (4
CRP, mg/l* 1.8 (0.8–4.1) 1.5 (0.6–3.7) 2.3 (1
Creatinine, mg/dl 0.94 (0.21) 0.94 (0.20) 0.96 (0
TC, mg/dl* 197 (35) 190 (27) 267 (3
LDL-C, mg/dl* 120 (31) 112 (24) 179 (2
HDL-C, mg/dl* 52 (15) 61 (14) 44 (8
Triglycerides, mg/dl* 107 (75–154) 82 (63–105) 189 (1
ean (SD) or median (interquartile range) reported. Across-group comparisons: *p  0.001; †p 
CHD  coronary heart disease; CRP  C-reactive protein; HC  hypercholesterolemia; HTG 
holesterol; other abbreviations as in Table 1.on CIMT and increased risk of prevalent CAC compared hith NL subjects. Other dyslipidemias also demonstrate
ssociations with CIMT or CAC, but not both.
Low HDL-C, which is independently associated with
HD (4), has an independent association with common
IMT only. Aging alone is a strong determinant of
rogression of CIMT. In the ARIC (Atherosclerosis Risk
n Communities) study, the average progression of mean
aximum common CIMT was 0.0065 to 0.010 mm/year
18). The cross-sectional difference in mean maximum
ommon CIMT in low HDL compared with NL was
pproximately 0.02 mm, roughly equivalent to 2 to 3 years
f aging. Combined hyperlipidemia and hypercholesterol-
mia each demonstrated a difference of 0.05 mm compared
ith normal, roughly equivalent to 5 to 8 years of aging. We
valuated common and internal CIMT separately because
here may be differences in the initiation and progression of
therosclerosis in these sites due to differences in blood flow
nd lipid effects. The internal CIMT may be more strongly
redictive of CVD events than the common CIMT (13). A
ecent meta-analysis, however, suggests that the specificity
f CIMT measurement location (e.g., internal vs. common)
s low in terms of clinical end points (19). Also, multiple
ifferent protocols which evaluate different carotid segments
tion of Lipid Parametersby Combination of Lipid Parameters
ia HC MetS Low HDL-C HTG
331 (7) 736 (15) 876 (18) 368 (8)
61 (10) 60 (10) 60 (11) 61 (10)
54 46 56 51
41 41 32 47
9 16 13 12
31 12 32 13
19 31 23 28
8.6 (6.8) 10.3 (7.8) 8.5 (8.3) 7.8 (6.5)
83 79 80 79
20 21 24 21
20 25 28 17
60 54 48 62
14 17 14 15
36 43 37 44
15 23 14 62
97 (13) 101 (13) 99 (13) 99 (13)
89 (9.1) 91 (9.5) 89 (9.7) 90 (9.9)
) 4.9 (3.4–7.5) 7.5 (5.3–10.6) 6.1 (3.9–8.8) 5.7 (4.0–5.7)
) 1.9 (0.9–4.2) 2.3 (1.1–4.4) 2.1 (0.8–4.7) 2.4 (1.1–5.9)
0.96 (0.19) 0.96 (0.22) 0.94 (0.25) 0.94 (0.22)
250 (22) 197 (28) 175 (26) 211 (27)
177 (19) 114 (26) 114 (24) 116 (25)
52 (12) 38 (6.0) 40 (6.2) 55 (11)
7) 106 (84–126) 201 (170–249) 105 (83–127) 181 (162–213)
hi-square for categorical variables, analysis of variance for continuous variables.
iglyceridemia; NCEP  National Cholesterol Education Program; NL  normolipemia; TC  totalmbinasified
bined
ipidem
)
0)
57
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September 21, 2010:1034–41 Lipid Combinations, CIMT, and CACzed controlled trials. This has made the standardization of
IMT in clinical practice very difficult.
Thus, combined hyperlipidemia, hypercholesterolemia,
nd low HDL were associated with increased CIMT.
solated hypertriglyceridemia was not independently asso-
iated with CIMT or CAC. In fact, there is conflicting
nformation regarding the association of isolated hypertri-
lyceridemia (fasting) with CHD risk after adjustment for
ther CVD risk factors. Our findings suggest that isolated
asting triglyceride elevations may be primarily a marker for
ther important CVD risk factors rather than a pathogenic
isk factor for subclinical atherosclerosis.
Subjects with MetS dyslipidemia did not have signifi-
antly increased mean maximum common or internal
IMT compared with NL subjects. However, the relative
isk of prevalent CAC was mildly but significantly increased
mong subjects with MetS (relative risk: 1.09; 95% confi-
ence interval: 1.01 to 1.17) compared with NL subjects.
AC and CIMT share similar risk factors with each other
nd with CHD. However, plaque formation and subsequent
alcium formation within the coronary arteries likely in-
olves complex and different biological pathways than
ntima-media thickening of the carotid artery wall. In
everal studies, CIMT and CAC were correlated with each
ther, but only moderately (20–23).
More powerful than the isolated dyslipidemia of MetS is
he aggregate of abnormalities that makes up the metabolic
yndrome, and it is the aggregate that has powerful effects
n subclinical atherosclerosis and CVD events (24,25). It is
Figure 1 Difference in Mean Maximum CIMT
(mm) Compared With NL by Lipid Parameters
The blue lines indicate mean maximum internal carotid intima-media thickness
(CIMT) and 95% confidence interval; and the red lines indicate mean maximum
common CIMT and 95% confidence interval (adjusted for age, race/ethnicity,
sex, clinical site, education, history of hypertension, current smoking status,
alcohol use, estrogen use among women, waist circumference, fasting glu-
cose, fasting insulin, C-reactive protein, and creatinine). HDL  high-density
lipoprotein; MetS  metabolic syndrome; NL  normolipemia.mportant to note that we are interested specifically in theuestion of whether, beyond all the associated features of
etabolic syndrome, the dyslipidemia alone carries risk for
ubclinical atherosclerosis as defined by CIMT and CAC.
mong participants classified with the dyslipidemia of
etS, 77% had the metabolic syndrome according to the
urrent NCEP/ATP-III criteria (26).
C-reactive protein, an inflammatory marker strongly
ssociated with metabolic syndrome, has recently been used
o stratify participants in a clinical trial (7). We examined
hether hsCRP dichotomized at 2 mg/l modified the
ssociation of combination of lipid parameters with CIMT
r CAC. Overall, hsCRP did not modify these associations.
his finding is congruent with the findings of others
egarding the independent association of hsCRP with CAC
n the MESA study (27).
Another issue of interest is whether race/ethnicity or sex
ontributes differentially to the relationships of combina-
ions of lipid parameters and subclinical atherosclerosis. We
id not find any significant interaction of race/ethnicity or
ex with combinations of lipid parameters for subclinical
therosclerosis, suggesting that race/ethnicity as broadly
efined or sex may not be important in assessing these
elationships. However, it is important to consider inade-
uate power to detect interactions for race/ethnicity or sex
r hsCRP. Also, race/ethnicity was self-identified and
ubject to misclassification and does not give any informa-
ion about genetic differences. However, there still may be
mportant environmental and social influences captured by
ace/ethnicity classification.
Our findings demonstrate the important impact of
DL-C on subclinical atherosclerosis, in combination with
ther lipid abnormalities or as the sole abnormality. How-
ver, we also demonstrate that other lipid abnormalities that
re not defined by LDL-C demonstrate evidence of in-
reased subclinical atherosclerosis, such as low HDL-C and
etS dyslipidemia. Current guidelines specify LDL cut
Figure 2 Relative Risk for Prevalent CAC
Compared With NL by Lipid Parameters
The blue lines indicate coronary artery calcium (CAC) mean and 95% confi-
dence interval (adjusted for age, race/ethnicity, sex, clinical site, education,
history of hypertension, current smoking status, alcohol use, estrogen use
among women, waist circumference, fasting glucose, fasting insulin, C-reactive
protein, and creatinine). RR  relative risk; other abbreviations as in Figure 1.
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Lipid Combinations, CIMT, and CAC September 21, 2010:1034–41oints as primary therapeutic targets for initiating lifestyle
r pharmaceutical therapy on the basis of various risk scores,
he most common being the Framingham risk score or
CEP variation of the Framingham risk score (2). There
re many people for whom lipid-lowering therapies would
ot be recommended based on Framingham/NCEP risk
core and current guidelines despite having dyslipidemias
nd/or subclinical atherosclerosis, including those specified
n this analysis.
Importantly, risk estimation has progressed beyond 10-
ear risk estimates. Analyses of life-time risk have been
reated to determine risks in younger cohorts (28). Recently,
dults 50 years of age with low 10-year CHD risk but
igh lifetime CHD risk demonstrated higher baseline
urden of subclinical disease and progression of subclinical
isease (29). Large prospective longitudinal studies have
emonstrated consistent and significant associations of in-
reased CIMT and CAC with incident risk of myocardial
nfarction and/or stroke (13,19,21,30). Both CIMT and
AC contribute to CVD prediction, although receiver
perator curves for incident CVD (CHD, stroke, and fatal
VD) were higher with CAC than CIMT in the MESA
tudy cohort (21).
In support of causal associations of lipids with subclinical
therosclerosis and CVD events, clinical trials of lipid-
owering therapy, especially statins, have demonstrated de-
reased progression of CIMT (31,32). Furthermore, statin
herapy decreases CVD events in both primary and second-
ry prevention of CVD without significant cost, considering
eneric statins, or significant risk following appropriate
uidelines for monitoring (33,34).
This study is observational, and we may not have con-
rolled for all possible confounders. However, our model
ncludes important covariates, and the appropriate func-
ional form for each covariate was evaluated. We defined
etS dyslipidemia as HDL 40 mg/dl for men and 50
g/dl for women to construct mutually exclusive categories.
he actual definition of low HDL when defining MetS is
40 mg/dl for men (50 mg/dl for women) (2). Only 5.4%
f men and women with MetS had an HDL-C equal to 40
r 50 mg/dl, respectively. Also, the definition of MetS
yslipidemia does not include the other nonlipid features of
he metabolic syndrome, so we could focus on the impact of
he dyslipidemia of MetS in isolation on subclinical athero-
clerosis. We appropriately excluded subjects receiving
ipid-lowering therapy because lipid-lowering therapy and
ts duration can significantly confound the relationship
etween lipids and CIMT. Finally, these are cross-sectional
ssociations, and therefore causality cannot be proved.
onclusions
yslipidemias, defined by combinations of lipid parameters
hat are commonly seen in clinical practice, were associated
ith increased subclinical atherosclerosis. Combined hyper-ipidemia and simple hypercholesterolemia, in which therimary abnormality was elevated LDL-C, were associated
ith increased subclinical atherosclerosis in both carotid and
oronary arteries in a nondiabetic population without CVD.
ace/ethnicity, sex, and hsCRP did not modify the associ-
tions between combinations of lipid parameters and CIMT
r CAC. These findings are widely generalizable, as the
ESA study participants were multiethnic persons who
ere free living in their respective communities spanning
he U.S. Furthermore, subclinical atherosclerosis was sig-
ificantly associated with combinations of lipid parameters
ndependent of other CVD risk factors in otherwise low-
isk populations. Greater efforts are needed to detect dys-
ipidemia in primary prevention and consider appropriate
reatment.
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